Last reviewed · How we verify

ADX-324 — Competitive Intelligence Brief

ADX-324 (ADX-324) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ADAR activator. Area: Genetic/Rare Disease.

phase 3 ADAR activator ADAR1/ADAR2 Genetic/Rare Disease Small molecule Live · refreshed every 30 min

Target snapshot

ADX-324 (ADX-324) — ADARx Pharmaceuticals, Inc.. ADX-324 is an ADAR enzyme activator that enhances adenosine-to-inosine RNA editing to modulate gene expression and protein function.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ADX-324 TARGET ADX-324 ADARx Pharmaceuticals, Inc. phase 3 ADAR activator ADAR1/ADAR2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ADAR activator class)

  1. ADARx Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ADX-324 — Competitive Intelligence Brief. https://druglandscape.com/ci/adx-324. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: